415 related articles for article (PubMed ID: 24838797)
1. Does subdivision of the "atypical" urine cytology increase predictive accuracy for urothelial carcinoma?
Bostwick DG; Hossain D
Diagn Cytopathol; 2014 Dec; 42(12):1034-44. PubMed ID: 24838797
[TBL] [Abstract][Full Text] [Related]
2. An institutional experience with The Paris System: A paradigm shift from ambiguous terminology to more objective criteria for reporting urine cytology.
Roy M; Kaushal S; Jain D; Seth A; Iyer VK; Mathur SR
Cytopathology; 2017 Dec; 28(6):509-515. PubMed ID: 28833848
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing urothelial carcinoma.
Veeramachaneni R; Nordberg ML; Shi R; Herrera GA; Turbat-Herrera EA
Diagn Cytopathol; 2003 Jun; 28(6):301-7. PubMed ID: 12768634
[TBL] [Abstract][Full Text] [Related]
4. Atypical Category of the Johns Hopkins Template Has Higher Risk of Malignancy than the Paris System but the Paris System Is More Applicable for Suspicious Category.
Celik B; Kavas G
Acta Cytol; 2023; 67(4):425-433. PubMed ID: 36731438
[TBL] [Abstract][Full Text] [Related]
5. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of perioperative methylene blue-stained and permanent Papanicolaou-stained urine cytology to detect patients with high-grade urothelial cancer or the urinary bladder. Part 1].
Rossi R; Jaeger T; Börgermann C; Furtkamp C; Moos Stahl R; Rübben H; vom Dorp F
Urologe A; 2007 Sep; 46(9):1145-7. PubMed ID: 17661004
[TBL] [Abstract][Full Text] [Related]
7. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology.
Skacel M; Fahmy M; Brainard JA; Pettay JD; Biscotti CV; Liou LS; Procop GW; Jones JS; Ulchaker J; Zippe CD; Tubbs RR
J Urol; 2003 Jun; 169(6):2101-5. PubMed ID: 12771727
[TBL] [Abstract][Full Text] [Related]
8. Cytokeratin 20 immunocytochemistry on urine sediments: A potential low-cost adjunct to cytology in the diagnosis of low-grade urothelial carcinoma.
Wadhwa N; Diwaker P; Lotha N; Arora VK; Singh N
Cytopathology; 2017 Dec; 28(6):531-535. PubMed ID: 28940433
[TBL] [Abstract][Full Text] [Related]
9. Application of The Paris System to atypical urine cytology samples: correlation with histology and UroVysion
Miki Y; Neat M; Chandra A
Cytopathology; 2017 Apr; 28(2):88-95. PubMed ID: 27601215
[TBL] [Abstract][Full Text] [Related]
10. Urine cytology findings in patients with biopsy-confirmed urothelial carcinoma in situ with plasmacytoid features.
Nichols MM; Reynolds JP; McKenney JK; Nicolas MM; McIntire PJ; Policarpio-Nicolas MLC
Cancer Cytopathol; 2021 Oct; 129(10):798-804. PubMed ID: 33900681
[TBL] [Abstract][Full Text] [Related]
11. The Johns Hopkins Hospital template for urologic cytology samples: parts II and III: improving the predictability of indeterminate results in urinary cytologic samples: an outcomes and cytomorphologic study.
VandenBussche CJ; Sathiyamoorthy S; Owens CL; Burroughs FH; Rosenthal DL; Guan H
Cancer Cytopathol; 2013 Jan; 121(1):21-8. PubMed ID: 23192913
[TBL] [Abstract][Full Text] [Related]
12. The value of the "suspicious for urothelial carcinoma" cytology category: a correlative study of 4 years including 337 patients.
Ton Nu TN; Kassouf W; Ahmadi-Kaliji B; Charbonneau M; Auger M; Brimo F
Cancer Cytopathol; 2014 Nov; 122(11):796-803. PubMed ID: 24909774
[TBL] [Abstract][Full Text] [Related]
13. Ureterorenoscopic biopsy and urinary cytology according to the 2004 WHO classification underestimate tumor grading in upper urinary tract urothelial carcinoma.
Straub J; Strittmatter F; Karl A; Stief CG; Tritschler S
Urol Oncol; 2013 Oct; 31(7):1166-70. PubMed ID: 22300757
[TBL] [Abstract][Full Text] [Related]
14. Application of the Paris Reporting System for Urine Cytology: The Three-Year Experience of a Single Tertiary Care Institute in Thailand.
Phruttinarakorn B; Plumworasawat S; Kayankarnnavee J; Lualon J; Pongtippan A
Acta Cytol; 2022; 66(2):134-141. PubMed ID: 34999581
[TBL] [Abstract][Full Text] [Related]
15. ProEx C as an adjunct marker to improve cytological detection of urothelial carcinoma in urinary specimens.
Moatamed NA; Rao JY; Alexanian S; Cobarrubias M; Levin M; Lu D; Apple SK
Cancer Cytopathol; 2013 Jun; 121(6):320-8. PubMed ID: 23364848
[TBL] [Abstract][Full Text] [Related]
16. [Urinary cytology of transitional-cell carcinoma].
Piazza G; Galia A; Cosentino A; Grasso G
Pathologica; 1995 Apr; 87(2):146-7. PubMed ID: 8532407
[TBL] [Abstract][Full Text] [Related]
17. The application of the Johns Hopkins Hospital Template on urine cytology.
Wu HH; Redelman M; Chen S; Grignon DJ; Cramer HM
Diagn Cytopathol; 2015 Aug; 43(8):593-7. PubMed ID: 25721938
[TBL] [Abstract][Full Text] [Related]
18. Neural network using combined urine nuclear matrix protein-22, monocyte chemoattractant protein-1 and urinary intercellular adhesion molecule-1 to detect bladder cancer.
Parekattil SJ; Fisher HA; Kogan BA
J Urol; 2003 Mar; 169(3):917-20. PubMed ID: 12576812
[TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the Paris System in atypical urinary cytology.
Mikou P; Lenos M; Papaioannou D; Vrettou K; Trigka EA; Sousouris S; Constantinides C
Cytopathology; 2018 Dec; 29(6):545-549. PubMed ID: 30066427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
